CA2373262A1 - Therapeutic uses of bpi protein products in humans with otitis media with effusion - Google Patents

Therapeutic uses of bpi protein products in humans with otitis media with effusion Download PDF

Info

Publication number
CA2373262A1
CA2373262A1 CA002373262A CA2373262A CA2373262A1 CA 2373262 A1 CA2373262 A1 CA 2373262A1 CA 002373262 A CA002373262 A CA 002373262A CA 2373262 A CA2373262 A CA 2373262A CA 2373262 A1 CA2373262 A1 CA 2373262A1
Authority
CA
Canada
Prior art keywords
bpi
leu
ser
val
bpi protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373262A
Other languages
English (en)
French (fr)
Inventor
Jan J. Grote
Maartje J. Nell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
XOMA TECHNOLOGY Ltd
Xoma Ltd
Xoma US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XOMA TECHNOLOGY Ltd, Xoma Ltd, Xoma US LLC filed Critical XOMA TECHNOLOGY Ltd
Publication of CA2373262A1 publication Critical patent/CA2373262A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002373262A 1999-05-24 2000-05-24 Therapeutic uses of bpi protein products in humans with otitis media with effusion Abandoned CA2373262A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13614899P 1999-05-24 1999-05-24
US60/136,148 1999-05-24
PCT/US2000/014496 WO2000071149A2 (en) 1999-05-24 2000-05-24 Therapeutic uses of bpi protein products in humans with otitis media with effusion

Publications (1)

Publication Number Publication Date
CA2373262A1 true CA2373262A1 (en) 2000-11-30

Family

ID=22471532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373262A Abandoned CA2373262A1 (en) 1999-05-24 2000-05-24 Therapeutic uses of bpi protein products in humans with otitis media with effusion

Country Status (6)

Country Link
US (1) US6670327B1 (https=)
EP (1) EP1181039A2 (https=)
JP (1) JP2003500363A (https=)
AU (1) AU5292300A (https=)
CA (1) CA2373262A1 (https=)
WO (1) WO2000071149A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
WO2004052236A2 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
AU2005282571A1 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
US20070173463A1 (en) * 2006-01-20 2007-07-26 Brechtelsbauer Paul B Method and composition for treating otitis media
AU2007221150B2 (en) * 2006-02-27 2012-09-20 Ahm Technologies, Inc. Eustachian tube device and method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
JP3040781B2 (ja) * 1987-08-11 2000-05-15 ニューヨーク ユニバーシティ 生物学的に活性な殺菌性／透過性増大蛋白質断片
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
WO1995032728A1 (en) * 1994-05-26 1995-12-07 Abbott Laboratories Inhibition of attachment of h. influenzae to human cells
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6350742B1 (en) * 1998-09-11 2002-02-26 Carter-Wallace, Inc. Compositions and methods for treating infections of the ear

Also Published As

Publication number Publication date
EP1181039A2 (en) 2002-02-27
WO2000071149A3 (en) 2001-06-28
WO2000071149A2 (en) 2000-11-30
JP2003500363A (ja) 2003-01-07
AU5292300A (en) 2000-12-12
US6670327B1 (en) 2003-12-30

Similar Documents

Publication Publication Date Title
AU730303B2 (en) Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal transplantation
US6652862B2 (en) Biologically active bactericidal/permeability-increasing protein fragments
US5912228A (en) Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
EP0834320B1 (en) Albumin as active ingredient for treating corneal and conjunctival lesion and dry eye
EP0754050A1 (en) Anti-gram-positive bacterial methods and materials
WO2003045976A2 (en) Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US6162788A (en) Uses of BPI protein products
US7985729B2 (en) Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
PT690720E (pt) Utilizacoes terapeuticas de produtos de proteina bactericida indutora de permeabilidade
US6767893B2 (en) Method of treating conditions associated with intestinal ischemia/reperfusion
WO1996030037A1 (en) Method of treating conditions associated with burn injuries
US6599880B1 (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
AU730307B2 (en) Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury
US6670327B1 (en) Therapeutic uses of BPI protein products in humans with otitis media with effusion
WO1995002414A1 (en) Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
AU744918B2 (en) Therapeutic uses of BPI protein products in cystic fibrosis patients
AU2005202199B2 (en) Therapeutic uses of BPI protein products in humans with otitis media with effusion
US20030194377A1 (en) Therapeutic uses of BPI protein products in cystic fibrosis patients
US6482796B2 (en) Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued